Company intelligence / Profile preview

DeepLab

Athens, Attica, Greecedeeplab.ai ↗

Ownership: Private
Development stage: Other

Overview

DeepLab is an innovative SME applying advanced AI and machine learning to life sciences. Its core offerings include in-silico drug screening, lead optimization, interpretable models for target identification/cancer classification, generative AI for synthetic biological data, and brain-computer interfaces focused on wellness. The company is actively seeking partnerships in ML-driven drug discovery and preclinical research. No clinical trial results are published yet.

Therapeutic areas: OncologyOther
Modalities: In-silico drug discovery and screeningGenerative AI for synthetic bio dataPrecision medicine toolsInterpretable models for target identification and cancer subtype classification
Industry: Drug Discovery Services

Partnerships

Seeking partners in pharma/biotech for ML-driven research but no major public partnerships listed yet.

Beyond the preview

Go deeper on DeepLab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DeepLab.

Explore the full profile